Burkhardt M, Mayordomo E, Winzer K-J, Fritzsche F, Gansukh T, Pahl S, Weichert W, Denkert C, Guski H, Dietel M, Kristiansen G
Institute of Pathology, Charité-Universitätsmedizin, Berlin, Germany.
J Clin Pathol. 2006 Apr;59(4):403-9. doi: 10.1136/jcp.2005.028209. Epub 2006 Feb 16.
Activated leucocyte cell adhesion molecule (ALCAM, CD166) is a cell surface member of the immunoglobulin superfamily. ALCAM expression has prognostic relevance in prostate and colon cancer.
To evaluate ALCAM protein expression in breast cancer by immunohistochemistry and to correlate expression levels with clinicopathological data.
162 primary breast carcinomas with a mean clinical follow up time of 53 months were immunostained using a monoclonal ALCAM antibody. The staining was evaluated as an immunoreactive score (IRS) and grouped into low v high for both membranous and cytoplasmic staining.
Intraductal and invasive carcinomas showed a higher ALCAM expression (median IRS 4 and 6 respectively) than normal breast tissue (IRS 2). In univariate survival analyses a significant association of high cytoplasmic ALCAM expression with shortened patient disease-free survival (mean (SD) five year non-progression rate, 69.4 (4.6)% v 49.4 (11.1)%, p = 0.0142) was found. In multivariate analyses of disease-free survival times, high cytoplasmic ALCAM expression (relative risk (RR) = 2.086, p = 0.026) and nodal status (RR = 2.246, p = 0.035) were significantly associated with earlier disease progression, whereas tumour grading (RR = 1.6, p = 0.052) was of borderline significance.
The data suggest that strong cytoplasmic ALCAM expression in primary breast cancer, as detected by immunohistochemistry, might be a new marker for a more aggressive breast cancer biology.
活化白细胞细胞黏附分子（ALCAM，CD166）是免疫球蛋白超家族的细胞表面成员。ALCAM表达在前列腺癌和结肠癌中具有预后相关性。
通过免疫组织化学评估乳腺癌中ALCAM蛋白表达，并将表达水平与临床病理数据相关联。
使用单克隆ALCAM抗体对162例原发性乳腺癌进行免疫染色，这些病例的平均临床随访时间为53个月。染色评估为免疫反应性评分（IRS），并根据膜性和细胞质染色分为低表达和高表达。
导管内癌和浸润性癌的ALCAM表达（中位IRS分别为4和6）高于正常乳腺组织（IRS为2）。在单变量生存分析中，发现高细胞质ALCAM表达与患者无病生存期缩短显著相关（平均（标准差）五年无进展率，69.4（4.6）%对49.4（11.1）%，p = 0.0142）。在无病生存时间的多变量分析中，高细胞质ALCAM表达（相对风险（RR）= 2.086，p = 0.026）和淋巴结状态（RR = 2.246，p = 0.035）与疾病早期进展显著相关，而肿瘤分级（RR = 1.6，p = 0.052）具有临界显著性。
数据表明，通过免疫组织化学检测，原发性乳腺癌中强细胞质ALCAM表达可能是侵袭性更强的乳腺癌生物学行为的一个新标志物。
